{"id":3180,"date":"2021-11-26T09:34:00","date_gmt":"2021-11-26T09:34:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3588631_AE88631_0"},"modified":"2021-11-26T09:34:00","modified_gmt":"2021-11-26T09:34:00","slug":"australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=3180","title":{"rendered":"Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel"},"content":{"rendered":"<div><img decoding=\"async\" src=\"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png\" class=\"ff-og-image-inserted\"><\/div>\n<p><span class=\"xn-location\">MELBOURNE, Australia<\/span>, <span class=\"xn-chron\">Nov. 26, 2021<\/span> \/PRNewswire\/ &#8212; Starpharma showed that 100% of evaluable patients with&nbsp;Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease.<\/p>\n<p><a target=\"_blank\" href=\"https:\/\/starpharma.com\/drug_delivery\/dep_cabazitaxel\" rel=\"nofollow noopener\">DEP<sup>\u00ae<\/sup> cabazitaxel<\/a>&nbsp;is a patented, detergent (polysorbate-80<sup>[1]<\/sup>)-free, nanoparticle version of the conventional cancer drug, Jevtana<sup>\u00ae<\/sup> &#8211; a leading oncology agent used to treat advanced prostate cancer. Sales of Jevtana<sup>\u00ae<\/sup> exceeded <span class=\"xn-money\">US$600 million<\/span> in 2020. <\/p>\n<p><a target=\"_blank\" href=\"https:\/\/starpharma.com\/\" rel=\"nofollow noopener\">Starpharma<\/a>&#8216;s interim results in Stage IV prostate cancer show that one or more efficacy signals<sup>[2]<\/sup> were observed in 100% of patients assessed following DEP<sup>\u00ae<\/sup> cabazitaxel treatment.<\/p>\n<ul type=\"disc\">\n<li>64% of patients with assessable tumours saw prolonged stable disease and significant reductions in tumour size for up to 36 weeks <\/li>\n<li>90% of patients with assessable PSA (Prostate Specific Antigen) tumour biomarker levels had a PSA reduction; &gt;50% of these patients achieved a PSA reduction of at least 50% <\/li>\n<li>83% of patients with secondary bone disease exhibited either no progression or an improvement in bone disease <\/li>\n<li>56%&nbsp;of evaluable patients had responses to all three measures evaluated<\/li>\n<\/ul>\n<p><a target=\"_blank\" href=\"https:\/\/starpharma.com\/news\/636\" rel=\"nofollow noopener\">Starpharma&#8217;s positive interim results<\/a>&nbsp;are particularly significant given all patients in this cohort had late-stage prostate cancer and had failed multiple anti-cancer treatments, in addition to surgeries and radiation, prior to entering the DEP<sup>\u00ae<\/sup> cabazitaxel trial.<\/p>\n<p>Importantly, patients treated with DEP<sup>\u00ae<\/sup> cabazitaxel also experienced less severe bone marrow toxicity, significantly lower rates of severe neutropenia and no instances of neutropenic sepsis, which are associated with conventional cabazitaxel. The&nbsp;absence of detergent-like polysorbate-80 in the DEP<sup>\u00ae<\/sup> cabazitaxel formulation eliminated the need for prophylactic corticosteroids and antihistamines, with no anaphylaxis or severe hypersensitivity reactions observed. This avoidance of long-term steroid use is attractive, particularly in prostate cancer patients where bone health can be a significant issue. <\/p>\n<p>DEP<sup>\u00ae<\/sup> cabazitaxel is one of Starpharma&#8217;s three internal clinical-stage DEP<sup>\u00ae<\/sup> assets, alongside DEP<sup>\u00ae <\/sup>docetaxel and DEP<sup>\u00ae <\/sup>irinotecan, which Starpharma intends to licence following phase 2. Starpharma also has a number of partnered DEP<sup>\u00ae<\/sup> programs including with AstraZeneca and Merck &amp; Co., Inc.<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tbody readability=\"5\">\n<tr readability=\"10.5\">\n<td class=\"prngen2\" readability=\"10\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">[1]&nbsp;Polysorbate 80 is a detergent-like substance, which is used to solubilise insoluble molecules, and which is a component of conventional cabazitaxel products, including Jevtana<sup>\u00ae<\/sup> and generic forms. <\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"4.5\">\n<td class=\"prngen2\" readability=\"6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">[2]&nbsp;Efficacy in the prostate cancer cohort in the trial was assessed referencing the applicable aspects of the internationally recognised Prostate Cancer Working Group (PCWG3) guidelines.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MELBOURNE, Australia, Nov. 26, 2021 \/PRNewswire\/ &#8212; Starpharma showed that 100% of evaluable patients with&nbsp;Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease. DEP\u00ae cabazitaxel&nbsp;is a patented, detergent (polysorbate-80[1])-free, nanoparticle version of the conventional cancer drug, Jevtana\u00ae &#8211; a leading oncology agent used to treat advanced prostate cancer. [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":3181,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-3180","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=3180\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel - My Blog\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia, Nov. 26, 2021 \/PRNewswire\/ &#8212; Starpharma showed that 100% of evaluable patients with&nbsp;Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease. DEP\u00ae cabazitaxel&nbsp;is a patented, detergent (polysorbate-80[1])-free, nanoparticle version of the conventional cancer drug, Jevtana\u00ae &#8211; a leading oncology agent used to treat advanced prostate cancer. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=3180\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-26T09:34:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel.png\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel\",\"datePublished\":\"2021-11-26T09:34:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180\"},\"wordCount\":392,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel.png\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180\",\"name\":\"Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel.png\",\"datePublished\":\"2021-11-26T09:34:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel.png\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel.png\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=3180#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=3180","og_locale":"en_US","og_type":"article","og_title":"Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel - My Blog","og_description":"MELBOURNE, Australia, Nov. 26, 2021 \/PRNewswire\/ &#8212; Starpharma showed that 100% of evaluable patients with&nbsp;Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease. DEP\u00ae cabazitaxel&nbsp;is a patented, detergent (polysorbate-80[1])-free, nanoparticle version of the conventional cancer drug, Jevtana\u00ae &#8211; a leading oncology agent used to treat advanced prostate cancer. [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=3180","og_site_name":"My Blog","article_published_time":"2021-11-26T09:34:00+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel.png","type":"image\/png"}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=3180#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=3180"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel","datePublished":"2021-11-26T09:34:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=3180"},"wordCount":392,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=3180#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel.png","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=3180","url":"https:\/\/transmediavictoria.net.au\/?p=3180","name":"Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=3180#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=3180#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel.png","datePublished":"2021-11-26T09:34:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=3180#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=3180"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=3180#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel.png","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel.png","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=3180#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/3180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3180"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/3180\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/3181"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}